Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Sep;9(3):345-357.
doi: 10.1007/s41030-023-00233-z. Epub 2023 Jul 20.

The 2023 GOLD Report: Updated Guidelines for Inhaled Pharmacological Therapy in Patients with Stable COPD

Paul D Terry  1 , Rajiv Dhand  2
Affiliations
Review

The 2023 GOLD Report: Updated Guidelines for Inhaled Pharmacological Therapy in Patients with Stable COPD

Paul D Terry et al. Pulm Ther. 2023 Sep.

Abstract

Over the past 22 years, annual GOLD Reports have documented important changes in guidance and recommendations for uniformly treating patients with chronic obstructive pulmonary disease (COPD) with the goal of improving outcomes in patients suffering from this condition. The most recent GOLD Report, released in 2023, shows continued refinement in several areas, including more precise definitions of COPD and exacerbations of COPD, a new set of parameters to assess exacerbation severity, an updated COPD assessment tool, updated guidelines for initial and follow-up treatment, new information regarding the association between pharmacological triple therapy and reduction in mortality, and new discussions of inhaler device choice and adherence to COPD medications. Whereas we do not address all of the new or updated material in GOLD's 2023 Report, we summarize key changes in GOLD's recommendations regarding inhalation therapy for stable COPD and frame these changes in the context of previous GOLD recommendations.

Keywords: Adherence to therapy; COPD; COPD treatment; GOLD reports; Inhaled pharmacotherapeutics.

PubMed Disclaimer

Conflict of interest statement

Dr Paul Terry discloses no personal, financial, or commercial conflict of interest related to this manuscript. Dr Rajiv Dhand is on Advisory Boards of Astra-Zeneca, GSK, and Boehringer Ingelheim; has received honoraria from UpToDate and Mylan; and has received research support from Mylan/Theravance and Viatris.

References

    1. Terry PD, Dhand R. Inhalation therapy for stable COPD: 20 years of GOLD reports. Adv Ther. 2020;37:1812–1828. doi: 10.1007/s12325-020-01289-y. - DOI - PMC - PubMed
    1. Global Initiative for Chronic Obstructive Lung Disease (GOLD), Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease (2023 Report). https://goldcopd.org/2023-gold-report-2/
    1. Skully JL. What is a disease? EMBO Rep. 2004;5:650–653. doi: 10.1038/sj.embor.7400195. - DOI - PMC - PubMed
    1. Celli B, Fabbri L, Criner G, Martinez FJ, Mannino D, et al. Definition and nomenclature of chronic obstructive pulmonary disease: time for its revision. Am J Respir Crit Care Med. 2022;206:1317–1325. doi: 10.1164/rccm.202204-0671PP. - DOI - PMC - PubMed
    1. White F. Application of disease etiology and natural history to prevention in primary health care: a discourse. Med Princ Pract. 2020;29:501–513. doi: 10.1159/000508718. - DOI - PMC - PubMed

LinkOut - more resources